Vaccine immunogenicity diphtheria toxoid, tetanus toxoid, aellular pertussis , whole-cell pertussis, mealses, mumps, rubella, hepatitis B. children
Conditions
Interventions
Health children were randomized to receive four doses of DTaP-IPV-HB-Hib as primary series and first booster vaccination, and Tdap-IPV as second booster vaccination at the age of four years. Antibody
Experimental Biological/Vaccine,Active Comparator Biological/Vaccine
DTaP-IPV-HB-Hib ,DTwP-HB-Hib + bOPV
Sponsors
National Reserach Council of Thailand (NRCT)
Eligibility
Sex/Gender
All
Age
5 Years to 6 Years
Inclusion criteria
Inclusion criteria: Health children who were enrolled in the original trial (ClinicalTrials.gov NCT02408926, TCTR20180926001 ) and received four doses of either DTaP-IPV-HB-Hib or DTwP-HB-Hib + bOPV as primary series and first booster vaccination, and Tdap-IPV as second booster vaccination at the age of four years.
Exclusion criteria
Exclusion criteria: 1. Immunocompromised status 2. Bleeding tendency 3. Parent refusal to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunogenicity 8 years antibody levels to diphtheria, tetanus, pertussis | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunogenicity 8 years Antibody levels to measles, mumps, rubella and hepatitis B | — |
Countries
Thailand
Contacts
Public ContactNasamon Wanlapakorn
Chulalongkorn University
Outcome results
None listed